Give more independence to the Scots—paired with a statement that there will be no more votes for a long time to come
The move comes as GM's blue-chip brand is finally considered in range of—if not quite on par with—the best German luxury rides
Unresolved economic conflicts simmer during a tenuous cease-fire
In becoming Oracle's chairman and chief technology officer, Ellison will leave the software giant he founded in the hands of co-chief executive officers Mark Hurd and Safra Katz
The popular premixed funds are supposed to get more conservative as retirement gets closer. What “conservative” means is open to interpretation
With "activity-based working," you lose your desk and gain your freedom—all for better efficiency
The NFL is facing its worst crisis in 50 years. Why is Commissioner Goodell so sure he won't lose his job?
Two dozen live shows will broadcast professors' ideas for 40 hours a week, serving as a way to broaden Wharton's reach
A report finds high default rates on franchise loans
Founders: Dr. Samir Patel and Dr. David Guyer
VC Investment over the last four quarters: $37.47 million
Founded in 2007, the 15-employee Ophthotech is a biotech company developing treatments for age-related macular degeneration, a common cause of vision loss in older adults. The co-founders' prior venture, Eyetech, was acquired by OSI Pharmaceuticals (OSIP) in 2005 in a deal valued at $900 million.
Key to startup success: "[Our] in-depth understanding of the specific specialty pharma space, coupled with an experienced management and venture investors, has been key to our success."